| Our Company

ExThera Medical develops extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter, and ONCObind™ Blood Filter for removing harmful substances from the bloodstream of patients.  

ExThera Medical’s extracorporeal products are in development for patients suffering from severe infections. Products are also being developed for the treatment of metastatic cancer.    

ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm with a focus on therapeutic applications to address antimicrobial resistance (AMR). From this collaboration, the application of pathogen and circulating tumor cell adsorption intellectual property was developed to what is now branded as the Seraph® 100 and ONCObind™ Procedure Hemoperfusion blood filters.

ExThera Medical is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual’s race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.   

                                                                                                                                                                                                                                                                    MM-00062 Rev B